贵州赤天化股份有限公司 独立董事 2024 年度述职报告 作为贵州赤天化股份有限公司（以下简称：公司）的独立董事，本人在 2024 年的工作中，忠实地履行法律法规以及《公司章程》赋予的职责，发挥独立董事 应有的作用，确保董事会决策的公平、有效。能够保持对相关法律法规的学习， 强化自觉保护社会公众股股东权益的意识，对控股股东行为进行有效的监督，维 护公司整体利益，维护全体股东尤其是中小股东的利益，促进了公司的规范运作。 根据《公司法》《证券法》和中国证监会及上海证券交易所相关法律法规的要求， 现将 2024 年度本人履行独立董事职责的情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 本人曾任渤海证券股份有限公司投资银行总部业务五部总经理、六部总经理， 上海瀚叶投资控股有限公司北京副总经理，2018 年 7 月至今任北京瀚元投资管 理有限公司 CEO。2024 年 9 月 5 日至今任厦门中创环保科技股份有限公司独立董 事。2020 年 9 月至今任贵州赤天化股份有限公司独立董事。 （二）是否存在影响独立性的情况进行说明 | （一）股东大会、董事会出席情况 | | --- | | ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥564,562,527.48, representing a 29.09% increase compared to ¥437,342,800.21 in the same period last year[3] - The net loss attributable to shareholders was ¥46,029,998.93, compared to a loss of ¥40,180,722.94 in the previous year, indicating a worsening performance[3] - The basic and diluted earnings per share were both -¥0.0273, compared to -¥0.0237 in the same period last year, reflecting a decline in profitability[3] - The weighted average return on net assets was -1.83%, a decrease of 0.31 percentage points from -1.52% in the previous year[3] - Comprehensive loss for Q1 2025 was ¥47,104,122.72, compared to a comprehensive loss of ¥39,778,587.93 in Q1 2024, indicating a 18.4% increase in comprehensive losses[16] - Net loss for Q1 2025 amounted to ¥46,029,998.93, compared to a net loss of ¥40,180,722.94 in Q1 2024, reflecting an increase in losses of 14.6%[16] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥83,847,294.01, compared to a negative cash flow of ¥19,046,680.96 in the same period last year[3] - The company's cash and cash equivalents increased to CNY 387,888,056.19 from CNY 345,938,195.46, reflecting a growth of approximately 12.09%[11] - The company's net cash increase for Q1 2025 was ¥32,664,822.12, contrasting with a net decrease of ¥82,403,536.40 in Q1 2024[20] - The total cash inflow from operating activities in Q1 2025 was ¥561,078,410.93, up from ¥410,443,291.17 in Q1 2024, representing a 36.7% increase[19] - The cash outflow from investment activities in Q1 2025 was ¥39,811,439.29, compared to ¥87,416,471.64 in Q1 2024, showing a decrease of 54.4%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,717,241,829.08, a decrease of 2.45% from ¥4,835,568,109.17 at the end of the previous year[4] - The company's total liabilities decreased to ¥2,217,600,931.42 in Q1 2025 from ¥2,290,770,107.14 in Q1 2024, a reduction of 3.2%[15] - Current assets totaled CNY 881,053,569.71, down from CNY 965,650,280.75, indicating a decrease of about 8.73%[13] - The total assets of the company were ¥4,717,241,829.08 in Q1 2025, down from ¥4,835,568,109.17 in Q1 2024, a decrease of 2.4%[15] - The total liabilities increased to ¥619,790,677.07 as of March 31, 2025, compared to ¥532,576,563.07 at the end of 2024[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 66,877[8] - The company has a significant shareholder, Guizhou Yuyang Trading Co., Ltd., holding 443,326,840 shares, which accounts for 26.25% of total shares[9] - The top ten shareholders include state-owned entities, with China Great Wall Asset Management Co., Ltd. holding 94,339,622 shares, representing 5.59%[9] Research and Development - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[11] - Research and development expenses for Q1 2025 were ¥12,647,110.06, down 28.5% from ¥17,680,650.57 in Q1 2024[15] Other Financial Metrics - The company reported a credit impairment loss of ¥770,467.61 in Q1 2025, compared to a gain of ¥130,960.35 in Q1 2024[16] - The company incurred financial expenses of 825,035.12 RMB in Q1 2025, compared to 976,173.16 RMB in Q1 2024, reflecting a decrease of approximately 15.5%[26] - The company received 93,000,000.00 RMB from financing activities in Q1 2025, indicating a strong inflow compared to the previous year[29]

Financial Performance - The company reported a negative retained earnings of -2,094.98 million RMB as of December 31, 2024, indicating no profit distribution for the year[5]. - The company has not provided any cash dividends, bonus shares, or capital reserve transfers due to the negative distributable profits[5]. - The company's operating revenue for the current period is 2,380,061,000, an increase of 5.98% compared to 2,245,779,000 from the previous year[23]. - The net profit attributable to shareholders of the listed company is -86,693,480, showing an improvement from -119,274,840 in the same period last year[23]. - The cash flow from operating activities for the current period is 376,973,100, representing a 14.92% increase compared to 307,992,942 from the previous year[23]. - The total assets at the end of the period are 4,835,568,000, an increase of 2.58% from 4,714,143,200 at the end of the previous year[23]. - The basic earnings per share for the current period is -0.0512, an improvement from -0.0704 in the previous year[24]. - The weighted average return on equity has increased by 1.05 percentage points to -3.34% compared to -4.39% in the previous year[24]. - The company reported a net profit attributable to shareholders of -40,180,722.94 in the first quarter, with a cash flow from operating activities of -19,046,680.96[27]. - The total net profit from non-recurring gains and losses for the current period is 7,632,446.58, significantly lower than 192,543,653.03 in the previous year[29]. - The company achieved a total operating revenue of 238,006.12 million yuan, an increase of 13,428.21 million yuan compared to the previous year, while the net profit attributable to shareholders was -8,669.35 million yuan, a decrease in loss of 3,258.14 million yuan[35]. Audit and Compliance - The audit report issued by Lianda CPA indicates a standard unqualified opinion, ensuring the financial report's authenticity and completeness[5]. - The company is committed to ensuring the accuracy and completeness of the annual report, with key personnel affirming the financial report's integrity[5]. - The company has engaged Lianda CPA for auditing services, ensuring compliance with regulatory standards[20]. - There are no instances of non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[7]. Business Operations and Segments - The company operates in three main business segments: chemical, medical services, and coal mining[88]. - The chemical segment's main products include urea, methanol, and compound fertilizers, with urea being a widely used nitrogen fertilizer[88]. - The medical services segment, represented by Daqin Hospital, focuses on oncology treatment and is built to national tertiary specialty hospital standards[89]. - The coal mining segment, operated by Anjia Mining, has a designed annual production capacity of 600,000 tons from the Huakui No. 2 coal mine[88]. - The company has a production capacity of 300,000 tons of synthetic ammonia, 300,000 tons of methanol, and 520,000 tons of urea, among other products, leveraging advanced technologies for production[96]. Market Trends and Projections - The company is collaborating with top research institutions to improve fertilizer efficiency and promote sustainable agricultural practices in Guizhou Province[38]. - The company is focusing on brand building and service enhancement in its medical services segment, including the establishment of a blood purification center and the introduction of advanced treatment technologies[40]. - The company is actively pursuing technological upgrades in its coal mining operations to improve safety and efficiency, including the implementation of mechanization and smart technology[41]. - The company anticipates a structural shift in demand for fertilizers, with industrial applications increasing to 30% of total demand[158]. - The healthcare market for cancer treatment in China exceeded 400 billion RMB in 2022 and is projected to surpass 600 billion RMB by 2025, with a CAGR of approximately 12%[162]. Challenges and Risks - The management has highlighted potential risks that may adversely affect the company's future strategic development and operational goals[7]. - The company faces significant challenges due to the increasing energy efficiency and carbon emission requirements imposed by national "carbon peak" and "carbon neutrality" policies, necessitating substantial investments in energy-saving and carbon-reduction technologies[171]. - The hospital sector is experiencing risks related to government policy changes that could impact service pricing and reimbursement standards, necessitating improved internal management and operational efficiency to mitigate these risks[172]. - Economic instability, including inflation and recession, may reduce patient willingness to seek medical care, prompting the company to diversify revenue streams and enhance service offerings[174]. Governance and Management - The company has established a complete and independent business system, ensuring independence in assets, personnel, finance, organization, and operations from the actual controller[180]. - The company has implemented a long-term mechanism to prevent fund occupation by the actual controller and its related parties, ensuring no violations occurred[181]. - The financial accounting system is independent and complies with the relevant accounting standards, with no shared bank accounts with the actual controller[181]. - The company has seen an increase in shareholding for some executives, with notable increases such as 147,500 shares for the executive vice president[186]. - The company has conducted several shareholder meetings, including the approval of the 2023 annual report and other significant resolutions[184]. Future Outlook - In 2024, the company plans to achieve revenue of CNY 240,034.86 million, with a net loss of CNY 6,325.59 million[167]. - The company aims to produce 59,000 tons of urea, 36,000 tons of synthetic ammonia, and 30,000 tons of methanol in 2024[167]. - For 2025, the company expects revenue of CNY 217,830.13 million, with a net loss of CNY 7,118.09 million[168]. - The company plans to produce 55,800 tons of urea and 33,790 tons of synthetic ammonia in 2025, with a scheduled maintenance affecting production for 30 days[168].

申万宏源证券承销保荐有限责任公司 关于贵州赤天化股份有限公司 2024 年度募集资金存放与使用情况 之 专项核查报告 独立财务顾问 申 厂宏源承销保荐 二〇二五年四月 申万宏源证券承销保荐有限责任公司(以下简称"申万宏源承销保荐"或"独 立财务顾问"）作为贵州赤天化股份有限公司（以下简称"赤天化"或"公司"） 发行股份购买资产并募集配套资金暨关联交易之独立财务顾问,根据中国证监会 《上市公司监管指引第 2 号――上市公司募集资金管理和使用的监管要求》、《上 海证券交易所上市公司自律监管指引第1 号 -- 规范运作》等有关规定,对赤天 化 2024 年度募集资金存放与使用情况进行了核查，具体核查情况如下: 一、募集资金基本情况 经中国证券监督管理委员会《关于核准贵州赤天化股份有限公司向贵州渔阳 贸易有限公司发行股份购买资产并募集配套资金的批复》(证监许可(2016)2005 号）核准,公司以非公开发行方式发行人民币普通股（A 股）327,787,021 股, 募集资金总额为人民币 1.969.999.996.21 元,扣除发行费等相关费用后,实际募 集资金净额为 1.943,799,996.25元。上述资金于 ...

报告期内：公司全资子公司贵州安佳矿业有限公司（以下简称：安佳矿业） 于2023年12月承接花秋二矿煤矿采矿权及附属资产，2024年为置入运营管理的第 一年，花秋二矿设计产能60万吨/年，受瓦斯超限整改频繁、团队磨合不足、设 备运营故障频发、政策性停产等影响，2024年煤炭开采不及预期，2024年度产煤 78,457.92吨，销售原煤77,266.42吨。 二、化工业务 1、主要产品的产量、销量及收入实现情况 | 主要产品 | 2024 | 年度生产量(万 | 2024 | 年度销售量(万 | 2024 | 年度营业收入（万 | | --- | --- | --- | --- | --- | --- | --- | | | | 吨) | | 吨) | | 元） | | 尿素 | | 68.96 | | 66.11 | | 131,051.28 | 证券代码：600227 证券简称：赤 天 化 公告编号：2025-030 贵州赤天化股份有限公司 2024 年年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根 ...

经核查独立董事范其勇、王朴、徐广的任职情况以及签署的相关自查文件， 除担任公司独立董事及董事会各相关专门委员会委员外，上述人员未在公司或公 司附属企业任职，也未在公司主要股东公司担任任何职务，与公司以及主要股东 之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系。 贵州赤天化股份有限公司董事会 对独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》的规定，贵州赤天化股份有限公司（以下简称：公司） 就公司在任独立董事范其勇、王朴、徐广的独立性情况进行评估并出具如下专项 意见： 董事会认为公司独立董事符合《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》中对独立董事独立性的相关要 求。不存在任何妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的 情况。 贵州赤天化股份有限公司董事会 二〇二五年四月二十八日 ...